|
Synonyms: PF-04383119 | PF04383119 | RN624
Compound class:
Antibody
Comment: Tanezumab is an investigational monoclonal antibody targeting nerve growth factor (NGF). NGF is a neurotrophin that regulates the development and survival of a select population of neurons through the binding and activation of the neurotrophic receptor tyrosine kinase 1 (TrkA receptor). Elevated levels of NGF have been associated with painful pathologies including diabetic neuropathy, fibromyalgia and osteoarthritis. Inhibition of NGF signalling has been explored for anti-pain potential.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical sequences are claimed in patent US7449616. |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 8941 | tanezumab |
| Synonyms |
| PF-04383119 | PF04383119 | RN624 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 230 |
| Other databases | |
| GtoPdb PubChem SID | 252166625 |
| Search PubMed clinical trials | tanezumab |
| Search PubMed titles | tanezumab |
| Search PubMed titles/abstracts | tanezumab |
| Wikipedia | Tanezumab |
